pharmaphorum May 12, 2022
German drugmaker Boehringer Ingelheim has sold an artificial intelligence-powered software platform it developed to monitor drug safety data to ArisGlobal, which provides cloud software to life sciences companies.
The platform – called BRASS (Benefit-Risk Analytic System) – was developed by Boehringer to unlock hidden patient safety signals from large data sets, and will be layered into ArisGlobal’s LifeSphere safety and pharmacovigilance platform.
Within LifeSphere – which is used by hundreds of life science firms – BRASS will be known as LifeSphere Clarity, said Boehringer.
The software can be used to conduct an initial analysis of adverse reactions to medications that have already been approved to identify potential side effects and undesirable events, and provides a decision-making tool for those working...
Today's Sponsors
Today's Sponsor